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Objective: To study epidemiologic features of and risk factors for intestinal colonization and infection by vancomycin- 
resistant enterococci (VRE) in cancer patients. 
Methods: During a 41-month period, over 7600 fecal samples and al l  samples from sterile sites from hospitalized cancer 
patients were screened for VRE. Species were identified and isolates analyzed by pulsed-field gel electrophoresis (PFGE) 
of Smal DNA restriction fragments. Antibiotic resistance was characterized by MIC determinations, and polymerase 
chain reaction for vanA, van& and vanC7 genes. Plasmid contents were analyzed before and after Pstl and Hindlll 
restriction, and by Southern hybridization with a vanA probe. Two case-control studies were performed to identify risk 
factors for colonization or infection by VRE, respectively. 
Results: Eighty-two isolates were recovered from 81 patients. Most (72%) isolates were Enterococcus faecium 
VanNvanA, with 37 different PFGE types, each of which was found in only one to four patients, except for type P1, which 
was found in 20 patients hospitalized over a 3-month period in the pediatric wards. Plasmid analysis suggested that only 
two types of plasmid were carrying gene vanA, as part of a transposon related to transposon Tn 7546 from reference 
strain E. faecium BM4147. Seventy-seven patients were colonized during the study period. Six of them became infected. 
Four patients were infected but not colonized. Only one patient died during the course of infection, but intestinal 
colonization persisted for months in the survivors. Case-control analysis revealed that cephalosporin treatment was a 
significant risk factor for colonization. No significant risk factor for infection was found in colonized patients. 
Conclusion: Colonization by VRE was mostly endemic and the colonized patients were not often infected. However, 
when clustered cases of colonization occurred, they were then associated with an increased rate of infection. 
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INTRODUCTION 
The intestinal tract is a recognized major source of 
Gram-negative bacteremia in cancer patients. Entero- 
cocci are also natural inhabitants of the intestinal tract 
[l] and cause a significant number of cases ofbacteremia 
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in cancer patients [2,3]. Because of their increasing 
resistance to antimicrobial agents, enterococcal infec- 
tions are often difficult to treat and require the use of 
glycopeptide antibiotics [4]. In addition, isolates of 
enterococci which are also resistant to glycopeptides 
have been described [S] and are referred to as vanco- 
mycin-resistant enterococci (VRE). The genetics and 
biochemistry of this resistance have been extensively 
studied and recently reviewed [6]. These VRE have 
been recognized as an increasing cause of infection in 
hospitalized patients [7-111. 
Since vancomycin is often used empirically in 
cancer patients against Gram-positive microorganisms, 
192 
M o u i i n  e t  a l :  V a n c o r n v c i n - r e s i s t a n t  e n t e r o c o c c i  in  c a n c e r  p a t i e n t s  193 
VRE represent a major threat that this regimen may 
be ineffective. 
In order to assess this risk, we performed a long- 
term surveillance study in patients hospitalized in a 
large cancer referral center and showed that although 
colonization was mostly endemic, clustered cases of 
colonization could occur and then be associated with 
an increased rate of infection. 
MATERIALS AND METHODS 
Surveillance of intestinal colonization 
From 1 December 1989 to 30 April 1993, a surveil- 
lance system was established to detect VRE intestinal 
colonization in patients hospitalized at  the Institut 
Gustave-Roussy, a 420-bed, tertiary-care, cancer 
referral treatment center located in the Paris (France) 
suburbs. Over that time, the clinicians were asked to 
obtain a fecal sample from their patients whenever 
they felt that they were at  risk of infection. All fecal 
specimens arriving in the central microbiology labora- 
tory were screened for the presence of VRE by plating 
the feces on bile esculin agar (Difco Detroit, Mich.) 
supplemented with 10 pg/mL of vancomycin (E. Lilly, 
Paris, France). This concentration was chosen because 
preliminary experiments (not shown) showed that: (1) 
it was highly selective for VRE, (2) the medium could 
be stored for up to 7 days at 4 °C  before use without 
appreciable loss of selectivity, and (3) it allowed ample 
growth of reference strains vanA Enterococcus faeciurn 
BM4147 [5], vanB Entevococcusfaecalis V583 [12], and 
vanC Entwococcus gallinarum BM4174 [ 131 (kindly 
provided by R .  Leclercq and l? Courvalin, Institut 
Pasteur, Paris, France) (data not shown). In addition, 
this concentration of vancomycin has been used by 
others [14] for selection of VRE isolates. 
After 48 h of incubation at  37"C:, species were 
identified using the API-20 Strep technique (Bio- 
Mtrieux, La B a k e  les Grottes, France) according to 
the recommendations of the manufacturer. 
Detection of cases of infection 
During the study period, all microbiological samples 
arriving in the laboratory for diagnosis were screened 
for the presence of enterococci on non-selective agar 
and on bile esculin agar without antibiotics. Clones 
identified as enterococci using the API-20 Strep tech- 
nique were further tested. Resistance to glycopeptide 
was suspected when a zone with a reduced diameter 
was observed in the disk susceptibility testing assay 
using vancomycin (30 pg) and teicoplanin (30 pg) disk, 
as recommended by the manufacturer (Diagnostic 
Pasteur, Paris, France). 
Antimicrobial susceptibility testing 
Susceptibility to gentamicin (500-pg disks) and 
ampicillin (30-pg disks) was assayed using the disk 
diffusion technique on Mueller-Hinton Agar (Diag- 
nostic Pasteur). Results were interpreted as previously 
described [ 151. Beta-lactamase production was assayed 
by the nitrocefin disk technique (Cefinase; BBL, 
Baltimore, Maryland). Minimum inhibitory concentra- 
tions of vancomycin and teicoplanin were determined 
by the agar dilution method [16]. VanA/VanB and 
VanC phenotypes were determined as described [6].  
Detection of van genes 
The presence of vanA, vanB or vanCl genes was 
detected using the polymerase chain reaction (PCR). 
The oligonucleotide primers chosen for amplification 
were selected fi-om the published sequences [13,17,18] 
with the assistance of Bisance Sofnvare [19]. The 
primers were complementary to bases 777 to 796 and 
the sequences were CGT TGA CAT ACA TCG TTG 
C G  and 1191-1172 (ATC C G T  C C T  CGC T C C  
CGA AT) and 444-425 (ATC ATC GCA TTC TCT 
GAG CC) and 605-624 (TGG C T C  TTG CAT CAA 
CTT GC) and 991-972 (TGG GAC AGT GAT CGT 
GGC GC) for genes vanA, vanB and vanCI, respec- 
tively. DNA extraction was performed, as described 
elsewhere [20], and 1 ng of DNA was added in 25 pL 
of reaction mixture containing: 15 mM Tris (pH 8.3); 
40 mM KC1; gelatin 100 mg/mL; 200 mM desoxy- 
nucleoside triphosphate (dATP, dCTF', dGTP, dTTP); 
1.75 m M  MgC12 for vanA PCR, 2.75 mM for vanB 
PCR,  and 2 mM for vanC PCR;  1 mM (each) primer; 
and 0.75 U of Taq DNA polymerase (Perkin-Elmer 
Cetus, Nonvalk, NC). A Perkin-Elmer Cetus model 
9600 DNA thermocycler was used for a 35-cycle 
amplification procedure with a first denaturation step 
for 2 min at 94"C, and then a 15-s denaturation step 
at  94 "C, a 15-s annealing step at  58 "C for vunA PCR,  
and at 60°C for both vanB and vanC PCRs, a 15-s 
extension step at 72"C, with the exception of the 
last cycle, in which this step lasted 10 min, followed by 
a holding step at 4"C, until analysis. P C R  products 
were electrophoresed in a 2% agarose gel in 1 x TBE 
buffer (89 mM Tris; 89 mM boric acid; 2 mM EDTA) 
for 90 min at 110 V, and stained with ethidium 
bromide. 
Amplimers were characterized as the expected 
intragenic fragments in vanA, vanB, or vanC, genes 
both with respect to size (415 bp, 344 bp and 386 bp, 
respectively), estimated on agarose gel electrophoresis, 
and restriction patterns, as described elsewhere 
[ 13,17,18]. 
TCT GC), 100-119 (GCG CAT CGC CGT C C C  
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Determination of pulsed-field gel electrophoresis (PFGE) 
types 
Genomic DNA was prepared by modifjring a pre- 
viously described procedure [21,22]. In the first step of 
suspension the cells were directly suspended in the 
lysis suspension without Big58, and the concentration 
of proteinase K was increased to 4 mg/mL. Genomic 
DNA was digested using restriction endonuclease 
SmaI (Boehringer Mannhein, Germany) following the 
recommendations of the manufacturer. Genomic DNA 
was then electrophoresed in a 1.5% agarose gel in x0.5 
TBE buffer by using a CHEF DR-11 apparatus (Bio- 
Rad, Richmond, Va). Two runs were used, the first 
lasting 8 h with initial and final switch times of 4 s, and 
the second lasting 20 h, with initial and final switch 
times of 4 and 30 s, respectively. For both runs the start 
ratio was 1, the voltage 200 V, and the temperature, 
15 "C. Gels were then stained with ethidium bromide. 
Reading of the gels was interpreted with the naked eye 
by two independent observers who matched their 
findings for agreement. Two isolates were considered 
identical when PFGE types differed from one another 
by only one or two visible bands, as previously 
described [22,23]. 
Determination of plasmid fingerprints and vanA hybridization 
Plasmid contents were characterized using whole 
plasmid analysis [24] and Southern blot hybridization 
with a vanA probe, either on unrestricted plasmidic 
DNA, or after PstI restriction to analyze the plasmidic 
background of uanA gene, or after HindIII restriction 
to analyze the structure of the vanA transposon, 
as recommended [25]. The vanA PCR procedure 
described above was used to prepare the uunA probe, 
except that 40 pM of digoxigenin 11-dUTP (Boeh- 
ringer Mannheim, Germany) was added to the PCR 
mixture. 
Hybridzation and detection conditions were as 
recommended by the manufacturer (Boehringer), 
except that 2.5% of blocking reagent was used in the 
detection step. 
Descriptive epidemiology and definitions 
Colonized patients were defined as carriers of an 
intestinal VRE isolate in at least one stool culture. 
Infected patients were defined as those in whom a VRE 
was isolated &om a normally sterile site. Colonized and 
infected patients were those in whom a VRE isolate 
was isolated both from a fecal sample and from a 
normally sterile site. The occurrence of cases of 
colonization, infection, and colonization and infection 
was plotted by month. 
Case-control studies 
A first case-control study was performed to analyze the 
risk factors for sporadic cases of intestinal colonization 
by VRE. Only cases of colonization which occurred 
during the first 36 months of the study were included, 
because, as will be described below, an outbreak of 
colonization and of infection occurred afterwards, and 
the risk factors might have been different during the 
two periods. A surveillance-for-detection period was 
defined as the time that elapsed between admission and 
the day on which the first positive stool culture was 
passed. Risks factors for colonization, including 
complete medical history of the underlying disease, and 
detailed treatments received during the 2 months 
preceding the first isolation of the VRE isolate, were 
recorded. Controls were chosen among patients who 
had not had any stool culture positive for VRE. In 
order to select such patients, we first defined a 
surveillance-for-detection period for the potential 
control patients as starting on the day of admission and 
ending after a number of days equal to that of the 
surveillance-for-detection period of the case patient to 
be matched. Then, the number of stool cultures 
actually performed in the potential controls during the 
surveillance-for-detection period was recorded and the 
final choice of controls was made after matching with 
the cases for underlying disease (leukemia versus solid 
tumor), ward, year and month of hospitahzation, age 
(k 5 years), sex, duration of survedlance-for-detection 
period and number of stool cultures performed for 
VRE detection during the survedlance-for-detection 
period. This last item was included to ensure that the 
probability of detection of intestinal VRE colonization 
was not lower in non-colonized controls than in 
colonized cases. Two controls were searched for 
matching with each case. However, only one adequate 
control was available for 20 cases. 
A second case-control study was performed to 
investigate risk factors for infection by VRE isolates 
among the colonized patients. Patients included as cases 
were those both colonized and infected (see above for 
definitions). Controls were chosen among patients who 
were only colonized, i.e. who were only carrying 
intestinal VRE and had no other positive culture. Two 
controls were matched with each case. Case patients 
and controls were matched for sex, age (k 5 years), 
underlying disease (leukemia versus solid tumor), ward, 
and year of hospitalization. The same risk factors used 
for the first case-control study were analyzed. 
Clinical data for both studies were obtained by 
consulting the clinical charts and the main fiame 
computer, and pertinent information was processed 
and analyzed using EpiInfo software [26]. The matched 
pairs odds ratio and the Mantel-Haenszel summary 
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chi-square were calculated for categorical data. The 
Kruskal-Wallis test was used for continuous variables. 
Microbiological results 
In all, 7672 stool cultures from approximatively 2250 
patients (estimated from the actual number of patients 
&om whom the last 1250 stool cultures were obtained) 
were screened during the study period. VRE isolates 
were isolated from 81 patients. In 71 (88%) a VRE 
isolate was isolated only from feces (one or multiple 
samples), in six (7%) a VRE isolate was isolated both 
from a fecal sample and another site (i.e. blood, four 
patients; pus, two patients), and lastly in four (6%) cases 
a VRE isolate was isolated only from a normally sterile 
site ( ix .  blood, three patients; pus, one patient with a 
double infection with two different VRE species 
isolated 2 months apart) but not from feces. In all 
instances when a VRE isolate was isolated from a 
normally sterile site, no other microorganism was 
present concomitantly in the culture. The distribution 
of the VRE cases of colonization and of infection over 
time is shown in Figure 1. 
The distributions of Enterococcus species, PFGE 
types and glycopeptide resistance phenotypes among 
the 82 VRE isolates are shown in Table 1. Seventy-five 
(91%) isolates were E. faecium. Seventy-two (88%) 
had a VanA phenotype and vanA genotype. The con- 
cordance between phenotype and genotype deter- 
minations of glycopeptide resistance was 100% (not 
shown). Forty-one isolates (50%) were resistant to 
ampicillin. None of them were penicillinase positive, 
and nor were they highly resistant to gentamicin (data 
not shown). 
Analysis of genomic DNA by PFGE among the 79 
isolates of E. faecium and E. gallinarum resulted in 41 
different types numbered P1 to P41, examples ofwhich 
are presented in Figure 2A (lanes 1 to 6). The number 
of isolates with the same type varied from 1 to 18 (data 
not shown). 
Plasmid fingerprinting was performed on 21 vanA 
VRE isolates with 15 different PFGE types. Sixteen 
different unrestricted plasmid profiles were obtained 
(not shown), but results of Southern blot hybridization 
on plasmidic DNA, with or without PstI restriction, 
showed that apparently only two types of vanA 
plasmids were present. The first type, referred to as 
pb20 plasmid, was present in all P1 and P16 PFGE type 
isolates, and appeared to be simdar to plasmid pIP816 
present in reference strain BM4147 (Figure 2B, lanes 1, 
2, 3 and 6). The other one, referred to as pblO plasmid, 
was present in all other tested isolates (for examples see 
Figure 2B, lanes 4 and 5). 
After Hind111 restriction the probe hybridized with 
a fragment of similar molecular weight irrespective of 
whether the plasmid was of pblO or pb20 type (not 
shown). This suggested that the vanA gene was carried 
on a transposon related to transposon Tn1546 in 
reference strain BM4147. 
Epidemiologic results 
Once all these data were taken into account, it was 
possible to distinguish two types of events from an 
epidemiologic standpoint. 
The first type of event comprised cases of coloniza- 
tion which occurred during the whole study period in 
patients hospitalized in various wards of the hospital 
(medicine, 25 (41%) patients; intensive care, one (1%) 
patient; pediatrics, 36 (58%) patients). Among the 49 
typed E. faecium strains isolated from such cases, no 
PFGE type was shared by more than four isolates. The 
epidemic distributions of the PFGE types of isolates 
which were found in two or more patients are shown 
in Figure 3. Except for isolates with P6, P18 and 
P22 PFGE types, which were isolated from patients 
Table 1 Distribution of species, PFGE types, glycopeptide resistance phenotypes and sites of isolation among 82 
vancomycin-resistant Enteroroccur isolates from patients hospitdzed at  the Institut Gustave-Roussy from 1 December 1989 to 
30 April 1993 
Number of Phenotypes Sites of isolation 
Number of different PFGE 
Species isolates (“A]) types VanA VanB VanC Feces Blood Pus 
E. fueciuwi 75 (91.4) 37 71 4 0 72” 6h 3.‘ 
E.  plliriarum 4 (5)  
E. fuecalis 1 (1.2) 
E. C U S . ~ C l ~ ~ V U S  1 (1.2) 0 0 1 0 1 0 
E. aviirm 1 (1.2) 1 0 0 0 0 1 
Total 82 (100) 41 72 5 5 77 7 4 
4 0 0 4 4 0 0 
0 1 0 1 0 0 - 
- 
- 
’ Two strains were isolated both from the feces and from pus. 
Four strains were isolated both from the feces and from blood 
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Months of survei 1 lance 
Figure 1 Epicurve of cases of intestinal colonization (0), infection in colonized patients (0) and infection in non-colonized 
patients (m), by vancomycin-resistant Enferococcus isolates in patients hospitalized at the Institut Gustave-Roussy from 
1 December 1989 to 30 April 1993. 
hospitalized several months apart, patients carrying 
isolates sharing a common PFGE type were to a large 
extent clustered in time, but only for isolates with P17 
and P21 types were the patients hospitalized in the same 
wards, suggesting possible cross-contamination. In the 
other cases, patients were hospitalized in wards located 
on different floors of the hospital. 
Results of plasmid typing showed that isolates with 
different PFGE types isolated from sporadic cases of 
colonization were apparently capable of harboring the 
same vanA plasmid. As shown in Figure 4, plasmid pblO 
was found in eight vancomycin-resistant E. faecium 
isolates with six different PFGE types and isolated from 
patients hospitalized over a 30-month period. 
Results of the first case-control study, which 
analyzed the risk factors for sporadic cases of intestinal 
VRE colonization, showed that the use of second- 
or third-generation cephalosporins (odds ratio=3.2, 
p = 0.047), and the number of days of treatment with 
cephalosporins ( p  = 0.006), were significantly associated 
with intestinal carriage of VFCE (Table 2). Pre-exposure 
to parented glycopeptides did not appear to be a 
significant risk factor (Table 2). Oral vancomycin, 
which was used in only five patients (two cases and 
three controls), was not significantly associated with 
VRE colonization. 
During the second part of the study period an 
outbreak occurred. Throughout December 1992 and 
January 1993, 20 new cases of colonization by E. 
fuecium vunA isolates were observed in the pediatric 
ward. All tested strains isolated from these patients 
shared the same P1 PFGE type and contained a pb20 
plasmid carrying the vanA gene (for examples, see 
Figure 2 Examples of Smal PFGE types (A) and v a d -  
probed blots of P3t I-chgested plasmid DNA (B). Lanes 1 to 
3, isolates with PFGE type P1 containing plasmid pb20; 
lane 4, isolate with PFGE type P11 containing plasmid 
pbl0; lane 5, isolate with PFGE type P24 containing 
plasmid pblO; and lane 6 ,  BM4147 strain containing 
plasmid pIP816. Lane without number is A-ladder 
molecular weight. 
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Figure 2A, lanes 1 to 3) .  During this period, 10 cases 
of infection occurred concurrently in the hospital 
(Figure 1). In five (50%) of these cases, VRE intestinal 
carriage was also detected. At the peak of the epidemic, 
stringent hygiene measures were implemented through- 
out the hospital and enteric isolation precautions were 
applied to VRE-colonized patients. This policy was 
followed by a return to baseline (Figure l), where VRE 
colonization and infection rates, have since remained 
(not shown). 
Concerning the patients who were infected over 
the 42 months of VRE surveillance, 11 cases of 
infection occurred in 10 patients (six colonized and 
infected, five infected only). As stated above, one 
patient was infected twice. Table 3 shows the clinical 
features and outcomes of these infected patients. Seven 
patients were bacteremic (six with an E. fuecium isolate 
and one with an E. casselijluvus isolate). All had a central 
venous catheter in place at the time of infection; 
however, none of them developed pain or erythema at 
the site of entry. Urine cultures were sterile in all seven, 
but stool cultures were positive in four with the same 
VRE E.faecium strain as that isolated in the blood. Two 
Figure 3 Epicurves of cases of colonization caused by 
vancomycin-resistant Enterococcus faecium isolates with PFGE 
types found in more than one isolate. 
other patients had intra-abdominal infections. The 
stool cultures of these two patients were positive for 
VRE. In patient no. 6, however, the VRE isolated 
respectively from pus and feces had different PFGE 
types. 
The length of hospital stay before infection ranged 
from 11 to 142 days (mean 45.5 days) in infected 
patients. All infected patients were neutropenic (< 500 
polynuclear cell/mm3) at the time of infection, and the 
duration of neutropenia before infection ranged from 4 
to 129 days (means 32.5 days). However, the second 
case-control analysis found no significant risk factor for 
VRE infection in colonized patients, neutropenia 
included (data not shown). 
Four E. faecium-infected patients received high 
doses of ampicillin, together with gentamicin. The 
E. casselijluvus bacteremic patient received teicoplanin. 
One E. faecium bacteriemic patient died 2 days after 
VRE isolation with symptoms consistent with septic 
shock, and death was directly attributed to VRE 
bacteremia, whereas three other patients ultimately 
died as a result of their underlying disease, respectively 
20, 35 and 42 days after VRE infection was diagnosed. 
VRE infection was implicated to a minor degree, if any, 
in the possible causes of death, since blood cultures 
were repeatedly sterile several days before death (not 
shown). In the three colonized and infected patients 
who survived the VRE bacteremic episode, long-term 
intestinal carriage persisted even after discharge from 
hospital (Table 3). 
DISCUSSION 
Altogether, our results show that, during the 42 months 
of the study, intestinal colonization occurred endem- 
ically in cancer patients hospitalized in our institute. 
Colonization was caused by multiple different VRE 
isolates. Subsequent infection, or infection without 
colonization, was an unlikely phenomena except when 
an outbreak of colonization occurred. 
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Figure 4 Epicurve of VRE isolates of various PFGE types 
carrying plasmid pblO. 
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Table 2 Matched relative risks of VRE colonization in case patients and controls during the endemic period (first case- 
control study) 
Cases Controls Odds 
(n=45) ( n  =70) ratio 95% CI p value Characteristics 
~~~ ~ ~~ ~ 
Matched characteristics: 
Sex (males) 
Age (years, mean +_ 50) 
Underlying disease 
Leukemia 
Solid tumor 
colonization (median, range) 
pedormed' (median, range) 
Intensive care unit 
Pediatrics 
Hemato-oncology 
Selected risk factors: 
Length of hospital stay before 
Number of stool cultures 
Ward during hospitalization 
Exposure to cephalosporins" 
Duration of cephalosporin 
treatment (days: median, range) 
Exposure to parenteral glycopeptide' 
Duration of parenteral glycopeptide 
treatment (days: median, range) 
Oral vancomycin 
30 
13 (1-78) 
42 
12 (1-71) 
NS 
ND 
8 
37 
12 
57 
N D  
ND 
14 (1-53) 14 (1-45) N D  
2 (0-8) 2 (1-7) N D  
1 
27 
17 
2 
41 
27 
ND 
N D  
ND 
3.2 1-9.0 41 42 0.047 
12 (0-38) 
38 
5 (0-38) 
49 
0.006 
0.1 2.2 0.8-6.7 
11 (0-39) 
2 
7 (0-37) 
3 
0.23 
0.85 2 0.3-14.2 
Cl =confidence limit intervals; NS=not significant: ND=not 
During the surveillance-for-detection period. 
Second- or third-generation cephalosporin. 
' Intravenous. 
done. 
In another study in cancer patients a high rate- 
6.5% of 61 patients-of VRE bloodstream infection 
was observed. However, the rate of colonization of 
these patients was very high [27]. Others [ll] have 
shown that VRE infections in non-cancer hospitalized 
patients, occurred only in a renal unit, where the rate 
of colonization was three times greater (I 5% versus 5%) 
than in patients hospitalized elsewhere in the hospital. 
In the absence of cases of infections, a 3.5% rate of 
carriage has been also reported for hospitalized patients 
The isolates we obtained were predominantly of 
the VanA/vanA phenotype/genotype. It seems unlikely 
that the low percentage of uunB isolates was due, even 
in part, to the relatively high concentration (10 mg/L) 
of vancomycin in our selective medium, since some 
isolates with a low level of resistance to vancomycin 
(uunB or uunC1 genotypes) were isolated, and others [8] 
have described the same proportion of VanA/uanA 
isolates among VRE isolates. 
We also obtained predominantly E.faecium isolates, 
whereas, within the genus Enterococcus, E. faeculis is 
usually considered to be responsible for the majority of 
infections [1,29]. However, a shift towards E .  faecium 
[7-91 has been reported recently. This could be 
[281. 
explained by the emergence of glycopeptide resistance, 
predominant in E. faecium isolates [3,30]. Indeed, it 
was shown in one study that the proportion of 
vancomycin-resistant E. faecium increased from 15% 
to 75% over a 3-year period, when the 3% propor- 
tion of vancomycin-resistant E. faecalis remained 
constant [8]. 
Our results showed that VRE colonization was 
either endemic or epidemic in our institute. When 
endemic, it was caused by many different isolates, as 
determined by PFGE typing. Such an intra-hospital 
diversity has been reported previously [3,31]. It seems, 
however, that during this period patient-to-patient 
transmission occurred in some instances. Such was the 
case for strains with P17 and P21 PFGE types. Two 
patients hospitalized in the same ward were colonized 
with each isolate, respectively, within a limited period 
of time. 
The mechanisms of transmission of VRE isolates 
have not been investigated in the present study. 
However, the hands of hospital personnel, as well as 
contaminated vectors, have been implicated in simdar 
instances [32-341. Nevertheless, the mechanism of 
acquisition remains unknown for patients colonized 
with an isolate not found in others. 
Table 3 Clinical features and outcomes of 10 patients infected with VRE (Institut Gustave-Roussy, Vdlejuif, France 
Time interval 
between detection 
PFGE type of colonization Outcome 
Case Age Underlying Source of (site of and infection 
Colonization Status no. (years) diseases isolates Species infection/stool) (days) Treatment Infection 
Colonized 1 38 Leukemia Blood culture E. fecirrm P19/P19 71 None Death D2' Still present 
and at death 
infected 2 12 Burkitt Blood culture E.  faeciirm Pl /P l  33 Ampicillin + Survival V w E  long-term" 
lymphoma 
3 7 Lymphoma Blood culture E. faeciirm Pl /P l  
4 3 CNS tumor Blood culture E. faerirrni Pl/P1 
5 6 Burkitt Intra-abdominal E. faecirrm P9/P9 
lymphoma abscess 
carcinoma abscess 
6 52 Intestinal Intra-abdominal E. faecirrm P2/P32 
gentamicin carriage 
Still present 
at death gentamicin 
Still present 
gentamicin at death 
carriage' 
gentamicin carriage 
18 Ampicillin + Death D20 
2 Ampicillin + Death D35 
3 None Survival VRE long-term 
3 Ampicillin + Survival VRE long-termd 
Infected 7 5 CNS tumor Blood culture E.)ecirrm P l /NA NA None Survival NA 
only 8 56 Carcinoma Blood culture E. casse/$aurrs P43/NA NA Teicoplanin Survival NA 
9 42 Leukemia Blood culture E. faecirrm Pl8/NA NA None Death D42 NA 
10' 72 Carcinoma Pus E. faecinm P2WNA NA None Survival NA 
Pus E. auiirnr P44/NA NA None Survival NA 
Patient died 2 days after the first positive blood culture was performed. 
bEight months of follow-up. 
"Four months offollow-up. 
'Three months of follow-up. 
'Patient no. 10 had two episodes of infection 2 months apart caused by Efaeci irm and E. nuittm uariA isolates, respectively 
NA=not applicable. 
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It has been suggested that the transposable nature 
of the genetic elements which encode for glycopeptide 
resistance in enterococci is conducive to dissemination 
of this resistance [7,25]. In our study the apparent 
relatedness of plasmids carried by isolates of various 
PFGE types suggests that a similar phenomenon could 
be involved. However, here again the precise mode of 
transmission remains unknown. 
Whatever the mechanism of genetic dissemination, 
we found an association between VRE colonization 
and previous treatments with second- or third- 
generation cephalosporins. Such treatments have been 
previously associated with the occurrence of noso- 
comial E .  fuecalij bacteremia [8]. However, the precise 
mechanisms whereby colonization is thus increased 
remain hypothetical. We did not find a significant 
association between colonization and parenteral 
exposure to glycopeptides. This might be explained by 
the low elimination of glycopeptides by the intestinal 
tract after parenteral injection. Two reports [33,35] 
found a significant link between VRE infection and 
previous glycopeptide treatments, but one [ll] found 
no association with VRE fecal carriage, as in our work. 
In all instances, colonization per se did not appear 
to confer a major risk of infection, since during the first 
30 months of the study period only 1/49 (2%) patients 
became infected with the colonizing VRE isolate. 
When the outbreak of colonization occurred, 
several patients became colonized by the same isolate 
over a short period of time, and several were infected. 
Of interest is the fact that some non-colonized patients 
developed an infection. The simultaneous presence of 
multiple colonized patients shedding VRE isolates in 
their feces might have increased the risk of transfer and 
of direct inoculation of sterile sites, in spite of the fact 
that the personnel had taken the precautions required 
for strict hygiene standards. This hypothesis would be 
consistent with the fact that we found no significant 
risk factors associated with infection in colonized 
patients (second case-control study). 
Among the 10 infected patients in the present 
study, only one, a 38-year-old man, died during the 
septic episode caused by a VRE isolate. Others 
have reported that the mortality associated with 
vancomycin-resistant E .  faecium isolates was lower in 
adult patients than that related to vancomycin- 
susceptible E. faecium isolates [36]. In another study of 
VRE infections, an overall mortality of 46.6% has been 
reported for patients with VRE bacteremia (371. 
However, VRE bacteremia cleared respectively in 8/9 
(88%), and in 5/6 (83%) patients in two other reports 
[ 11,381. Patients with peritoneal dialysis-associated 
peritonitis due to VRE also seem to have a fair 
prognosis [39]. 
Altogether, the prognosis of VRE infections in 
our study appeared related to that of the underlying 
disease. This has also been observed by others [ll]. The 
infected and colonized patients remained colonized 
even when the infectious episode had cleared. Such 
prolonged colonization has been reported previously 
both in oncology [27] and in non-oncology [ I l l  
patients. So far, however, no effective decontamination 
regimen has been reported [27]. 
Since curative treatment is also &fficult, it appears 
that the prognosis of VRE infections and colonization 
remains dependent on preventive measures [40]. 
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